Clinical Trial Update: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Secukinumab for plaque psoriasis with coexisting NAFLD was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Psoriasis, Non-alcoholic Fatty Liver Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-02-08